Topiramate Treatment for SSRI-Induced Weight Gain in Anxiety Disorders
J Clin Psychiatry 2002;63:981-984
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Antidepressants, including selective
serotonin reuptake inhibitors (SSRIs), have been associated with
significant weight gain, a problem that frequently leads to
noncompliance and premature discontinuation of treatment.
Topiramate is a novel anticonvulsant that has also been used as a
mood stabilizer and augmentation agent in mood disorders.
Topiramate has been observed to have an interesting side effect
of weight loss in some individuals. In this study, topiramate was
added to the treatment regimen of patients with a primary DSM-IV
anxiety disorder who had experienced substantial SSRI-induced
weight gain, in an attempt to induce weight loss.
Method: Topiramate was added to SSRI treatment
in 15 anxiety disorder patients, starting at a dose of 50 mg/day
and titrating up to a target daily dose of 100 mg/day, with a
maximum dose of 250 mg/day. Subjects' weight was measured at
baseline and after 5 and 10 weeks of treatment.
Results: Before topiramate treatment,
SSRI-treated subjects in this sample had gained a mean of 13.0 ±
8.4 kg (28.6 ± 18.5 lb). After the addition of a mean dose of
135.0 ± 44.1 mg/day of topiramate for approximately 10 weeks,
subjects lost a mean of 4.2 ± 6.0 kg (9.3 ± 13.3 lb).
Conclusion: Topiramate may have a role in
managing SSRI-induced weight gain in anxiety disorder patients.